oncbrain — oncology meeting digest

NRG Oncology RTOG 0539

Tue, 09 Jun 2026 00:00:00 GMT

[Early signal] 10-yr PFS 85.2%, 72.2%, 42.5% for low/intermediate/high-risk meningioma with risk-adapted observation or RT (median f/u ~12yr). Eligible: WHO grade 1-3 meningioma, post-resection (GTR or STR), newly-diagnosed or recurr

RAPCHEM (BOOG 2010-03)

Tue, 09 Jun 2026 00:00:00 GMT

[Early signal] 10-yr locoregional recurrence 2.9% overall with risk-stratified RT de-escalation after NAC + surgery in cN1 breast cancer. Eligible: Breast cancer cT<5cm cN1-3, receiving NAC prior to BCS or mastectomy

RAD-IO

Sat, 30 May 2026 00:00:00 GMT

[Early signal] 12-month DFS 80% (40/50; 95% CI 0.67-0.89) with durvalumab + chemoRT in MIBC, clearing GO threshold ≥75%; single-arm. Eligible: MIBC cT2-T3, 13% node-positive, 75% prior neoadjuvant chemo, median age 69

MIBC Management Post-pCR / Bladder-Sparing Session

Sat, 30 May 2026 00:00:00 GMT

[Early signal] Durvalumab + CRT (55 Gy/20 fr) feasible in 54 MIBC (87% full RT); pCR after NAC carries 85% 5-yr OS per SWOG 8710. Eligible: MIBC (cT2-4a N0), curative-intent bladder-sparing candidates

A-DREAM (ALLIANCE mAPMS)

Sat, 30 May 2026 00:00:00 GMT

[Early signal] ADT+ARPI interruption in mHSPC: 41% treatment-free with eugonadal T at 18mo (1° EP); 38.5% still off-tx at 26.9mo FU. Eligible: mHSPC achieving PSA<0.2 after ≥18-24mo ADT+ARPI, low-volume predominant

ARACOG (AFT-47)

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] MCCD median -36.1 (ENZ) vs -15.8 (DAR) at 24wk, p=0.009; enzalutamide caused significantly greater cognitive decline. Eligible: mHSPC, nmCRPC, or mCRPC on ARSI; cognitive toxicity a concern

CHRYSALIS-2 (1L Ami+Laz, Atypical EGFR+)

Sat, 30 May 2026 00:00:00 GMT

[Early signal] Median OS 41.0 mo (95% CI 27.7-NE) with ami+laz in 1L atypical EGFR+ advanced NSCLC; single-arm, n=49. Eligible: Advanced NSCLC, atypical EGFR mutation, treatment-naive

ESAONA

Sat, 30 May 2026 00:00:00 GMT

[Challenges SOC] Intracranial ORR 95.5% vs 79.6% (p=0.0004), iPFS HR 0.46 favoring asandeutertinib over osimertinib in 1L EGFR+ NSCLC with brain mets. Eligible: 1L EGFR-mutated NSCLC with active brain metastases

PREPEC

Sat, 30 May 2026 00:00:00 GMT

[Confirmatory] BREAST-Q chest score 79.2 vs 74.3 (diff 4.8, p=0.01) favoring pre-pectoral IBBR; implant loss 21% vs 15%. Eligible: Nipple-sparing or skin-sparing mastectomy for breast cancer treatment or risk re

PEACE V–STORM

Fri, 22 May 2026 00:00:00 GMT

[Early signal] 4-yr MFS 76% (ENRT) vs 63% (MDT), HR 0.62 favoring elective nodal RT for PET+ pelvic nodal prostate oligorecurrence. Eligible: Pelvic nodal oligorecurrence (≤5 PET+ nodes), prostate, post-radical tx, PS 0-1

INRT-AIR & DARTBOARD (ENI omission, HNSCC)

Mon, 18 May 2026 00:00:00 GMT

[Early signal] 5-yr solitary ENI recurrence 0% in 117 HNSCC pts on AI-assisted INRT omitting elective nodal fields. Eligible: HNSCC oropharynx/larynx/hypopharynx, stage I-IVB, definitive CRT candidates

EXTEND Trial

Mon, 18 May 2026 00:00:00 GMT

[Confirmatory] PFS HR 0.54 (95% CI 0.41-0.72, p<0.001) favoring MDT+SOC across histologies in phase II oligometastatic basket RCT; basket-specific signals identified. Eligible: Oligometastatic solid tumors, 1-5 mets, 6 histology baskets

FASTRACK II (TROG 15.03)

Mon, 18 May 2026 00:00:00 GMT

[Early signal] 100% LC at 84 months in primary RCC (N=70) treated with SABR; G3 AE 10%, no grade 4 events or cancer deaths. Eligible: Inoperable/surgery-declining primary RCC, T1b-dominant, median age 77

OLIGOMA

Sun, 17 May 2026 00:00:00 GMT

[Early signal] mPFS 35.8 vs 20.4 mo, HR 0.48; first RCT positive for MDT in oligometastatic breast cancer. Eligible: Metastatic breast, ≤5 mets, any systemic therapy line

RAPCHEM

Sun, 17 May 2026 00:00:00 GMT

[Early signal] 10yr locoregional recurrence <3% with nodal-response-guided RT de-escalation after neoadjuvant in breast cancer. Eligible: Node-positive breast cancer achieving pathological nodal response after neoadjuv

EXTEND

Sun, 17 May 2026 00:00:00 GMT

[Early signal] Phase II RCT of MDT added to SOC for oligometastatic solid tumors, all histology baskets; no effect size in source tweet. Eligible: Oligometastatic solid tumors, multiple histologies, all disease sites, systemic

RADIOSA

Sun, 17 May 2026 00:00:00 GMT

[Caveats dominate] Post-hoc: SBRT + 6mo ADT vs SBRT alone in oligorecurrent prostate; median MFS 16.6mo vs NR, HR 0.39, p=0.0012. Eligible: Oligorecurrent prostate cancer, SBRT candidates, median f/u ~4yr